Global Glucagon Market By Product Type (Kits, Injection, Powder/Solution), By Application (Emergency Use, General Use, Diagnostic & Motility, Other Applications), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019–2029
- Published date: Apr 2022
- Report ID: 19431
- Number of Pages: 212
- Format:
- keyboard_arrow_up
Market.us announces publication of its most recently generated research report titled, “Global Glucagon Market by Product Type (Kits, Injection, Powder/Solution), By Application (Emergency Use, General Use, Diagnostic & Motility, Cardiogenic Shock, Other Applications) and by Region – Global Forecast to 2028.”, which offers a holistic view of the Global Glucagon Market through systematic segmentation that covers every aspect of the target market.
The Global Glucagon Market is projected to be US$ 461.0 Mn in 2019 to reach US$ 837.0 Mn by 2029 at a CAGR of 6.2%.
The blood sugar level is an essential part of the overall health of the human body. When the blood sugar level becomes low, individuals might feel tired and disoriented. Blood sugar (Glucose) control includes various complex hormonal systems, one of which is glucagon. Glucagon is a metabolic hormone that plays a vital role in controlling blood sugar levels in the human body. Glucagon secreted by alpha cells of the pancreas, which discharged into the bloodstream. Glucagon hormone is also available in drug form which is used to treat severe hypoglycemia (low blood sugar). Glucagon hormone works together with the insulin hormone to maintain blood sugar at the right level in healthy individuals. Glucagon hormonal drug received FDA approval on November 14, 1960. Generally, glucagon is available in the form of intravenous, intramuscular or subdermal injection. Glucagon may cause some side effects such as vomiting, nausea, itching, and rash. Sometimes individuals may get difficulties in breathing and lost consciousness.
trending_up Total Revenue in 2018$461.0 Mn
trending_up Market CAGR of the Next Ten Years6.2%
no_encryption Market Value (US$ Mn), Share (%) and Growth Rate (%) Comparison 2012-2028Purchase this report or a membership to unlock the market value (US$ Mn), share (%) and growth rate (%) comparison for this industry.- By Type
- By Region
- By Application
no_encryption Leading Companies Financial HighlightsPurchase this report or a membership to unlock the leading companies financial highlights for this industry.trending_up Market Revenue of the Next Ten Years$837.0 Mn
Increasing prevalence and incidence of hypoglycemia in diabetes patients, coupled with the rising innovations in non-injectable emergency glucagon, are major factors driving the growth of the global market. Growing advancements in therapies & drugs and rising funding by leading organizations to improve health care infrastructure are driving the growth of the target market. Increasing heart-related problems among aging population indirectly fueling global glucagon market growth, as glucagon works as a guardian of the heart against catecholamine surge. Change in the lifestyle pattern, obesity, and bad eating habits such as an unhealthy diet are factors that increase the prevalence of diabetes, which in turn increase demand for glucagon. Moreover, rowing advancements in therapies & drugs and rising funding by leading organizations to improve health care infrastructure are driving the growth of the target market.
Global Glucagon Market Revenue (US$ Mn), 2019–2029
Moreover, increasing support from Food and Drug Administration (US–FDA) for the development of advanced therapies and drugs for the treatment of hypoglycemia is a factor offering lucrative revenue growth opportunity for manufacturers in the target market
However, Lack of awareness regarding the use of glucagon or low adoption rate in developing countries such as India, China, and Brazil, etc. is another factor that creates a negative impact on market growth
Global glucagon market is segmented on the basis of product type, application, and region. On the basis of product type, the market is segmented into Kits, Injection, Powder/Solution. Among product type, Kits segment is account for a major share. On the basis of application, the market is segmented into Emergency Use, General Use, Diagnostic & Motility, Cardiogenic Shock, Other Applications. The Emergency Use segment accounts for a majority share in the Global Glucagon market.
Global Glucagon Market Attractiveness Index by Application Type, 2019
On the basis of region, the market is segmented into North America, Europe, APAC, South America and MEA. North America accounts for the majority share in the global Glucagon market, owing fully developed and mature market
The research report on the Global Glucagon Market includes profiles of some of the major companies such as Novo Nordisk A/S, Eli Lilly & Co, Fresenius SE & Co. KGaA, Torrent Pharmaceuticals Ltd., Xeris Pharmaceuticals, Inc., Svar Life Science AB, Taj Pharmaceuticals Ltd.
Key Market Segments:
Type
- Kits
- Injection
- Powder/Solution
Application
- Emergency Use
- General Use
- Diagnostic & Motility
- Cardiogenic Shock
- Other Applications
Key Market Players included in the report:
- Novo Nordisk A/S
- Eli Lilly & Co
- Fresenius SE & Co. KGaA
- Torrent Pharmaceuticals Ltd.
- Xeris Pharmaceuticals Inc.
- Svar Life Science AB
- Taj Pharmaceuticals Ltd.
For the Glucagon Market research study, the following years have been considered to estimate the market size:
Attribute Report Details Historical Years
2016-2020
Base Year
2021
Estimated Year
2022
Short Term Projection Year
2028
Projected Year
2023
Long Term Projection Year
2032
Report Coverage
Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.
Regional Scope
North America, Europe, Asia-Pacific, South America, Middle East & Africa
Country Scope
United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa
- Novo Nordisk A/S Company Profile
- Eli Lilly & Co
- Fresenius SE & Co. KGaA
- Torrent Pharmaceuticals Ltd.
- Xeris Pharmaceuticals Inc.
- Svar Life Science AB
- Taj Pharmaceuticals Ltd.
- settingsSettings
Our Clients
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |